

COMPANY SANITIZED

8EHQ-0193-58155

UNIROYAL
CHEMICAL

UNIROYAL CHEMICAL COMPANY, INC.
World Headquarters
Middlebury, Connecticut 06749

Health & Regulatory Compliance Department (HRC)

January 21, 1993

Document Processing Center (TS-790)
Attn: 8(e) Coordinator
Office of Pollution, Prevention and Toxics
U.S. Environmental Protection Agency
401 M Street, S.W.
Washington, D.C. 20460

93 JAN 26 AM 9:22

Re: TSCA 8(e) Submission HQ0792-5815


Dear Coordinator:

This letter is pursuant to a telephone conversation with Cynthia Lewis, Esq., an attorney in Region V concerning confidential business information claims for the above mentioned section 8(e) submission. Based on that conversation, the Uniroyal Chemical Company, Inc. voluntarily withdraws CBI claims to the Chemical Abstracts Service number and chemical name for the material disclosed in this submission.

Therefore, we are resubmitting confidential and non-confidential versions of the cover letter for this document. We wish to maintain CBI claims for the product's trade name.

Please let me know if I can be of further assistance. I can be reached at (203) 573-3125.

Sincerely yours,



Howard S. Friedman, Ph.D.
Corporate Regulatory
Scientist

HSF356/cd

cc: R. Cardona, Bethany

8EHQ 92 5815 5
8993 00000 685

2 Pgs.

0 0 0 3

COMPANY SANITIZED
NON-CONFIDENTIAL

**UNIROYAL
CHEMICAL**

UNIROYAL CHEMICAL COMPANY, INC.
World Headquarters
Middlebury, Connecticut 06749

Health & Regulatory Compliance Department (HRC)

January 21, 1993

93 JAN 26 AM 9:22

NTS DOCUMENT RECEIVED

Document Processing Center (TS-790)
Attn: 8(e) Coordinator
Office of Pollution Prevention and Toxics
U.S. Environmental Protection Agency
401 M Street, SW
Washington, D.C. 20460

Dear Coordinator:

This letter is to inform you of preliminary results on the health effects studies of CAS No. 119738-06-6, (+)-tetrahydrofurfuryl-(R)-2-[4-(6-chloroquinoxaline-2-yloxy)phenoxy] propionate, generic name: Quinoxaline Phenylether.

An unaudited microscopic pathology report on this substance showed the following results: In a two year bioassay in male and female rats, microscopic observations revealed that treatment-related effects were noted in the livers in males and females. In particular, these changes included hypertrophy and hyperplasia of hepatocytes, bile stases, hepatocellular adenomas and carcinomas.

Thyroid glandular changes, secondary to hepatocellular hypertrophic activity were also noted. Treatment related changes of the testis in high dose males consisting of degeneration of the seminiferous tubules were observed along with an increased incidence of Leydig cell tumors.

These results, while of a preliminary, unaudited nature, show compound related effects under the experimental conditions of these studies. We are reporting these results to the EPA pursuant to the conditions set out under Section 8(e) of TSCA. Unaudited data tables are included as part of this submission.

Please do not hesitate to call me if I can be of further assistance.

Sincerely yours,



Howard S. Friedman, Ph.D.
Regulatory Scientist

HSF354/cd
attachment

0 0 0 4